Comparing safety and efficacy of first‐line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Cancer

• Publication date

  2009-06-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cncr.24305PMID 19382200
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Global cancer statistics

  2011cited by this paper
• Barriers to recruiting underrepresented populations to cancer clinical trials: A systematic review

  2008cited by this paper
• Phase III trial of chemotherapy with or without irinotecan in the front-line treatment of metastatic colorectal cancer in elderly patients (FFCD 2001–02 trial). Results of a planned interim analysis

  2008cited by this paper
• Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials.

  2008influential reference
• Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.

  2007cited by this paper
• Provider roles in the recruitment of underrepresented populations to cancer clinical trials

  2007cited by this paper
• Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis.

  2007cited by this paper
• Front-line Bevacizumab in combination with Oxaliplatin, Leucovorin and 5-Fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study

  2007cited by this paper
• Managing older patients with colorectal cancer.

  2007cited by this paper
• Severe diarrhea in patients with advanced-stage colorectal cancer receiving FOLFOX or FOLFIRI chemotherapy: the development of a risk prediction tool.

  2007cited by this paper
• Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.

  2007cited by this paper
• FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer

  2007cited by this paper
• Treatment tolerance and efficacy in geriatric oncology: a systematic review of phase III randomized trials conducted by five National Cancer Institute-sponsored cooperative groups.

  2007cited by this paper
• FOLFOX-4 Regimen as First-Line Chemotherapy in Elderly Patients with Advanced Gastric Cancer: A Safety Study

  2007cited by this paper
• Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer.

  2006influential reference
• Effectiveness of strategies to recruit underrepresented populations into cancer clinical trials

  2006cited by this paper
• FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)

  2006cited by this paper
• Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention

  2006cited by this paper
• A Randomised Comparison Between 6 Months of Bolus Fluorouracil/Leucovorin and 12 Weeks of Protracted Venous Infusion Fluorouracil as Adjuvant Treatment in Colorectal Cancer

  2006cited by this paper
• Elderly Patients with Advanced Colorectal Cancer: Tolerability and Activity of Chemotherapy

  2005cited by this paper
• Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study.

  2005influential reference
• Reduced Dose Intensity FOLFOX-4 as First Line Palliative Chemotherapy in Elderly Patients with Advanced Colorectal Cancer

  2005cited by this paper
• Global Cancer Statistics, 2002

  2005cited by this paper
• Combination of Irinotecan (CPT-11) plus 5-Fluorouracil and Leucovorin (FOLFIRI Regimen) as First Line Treatment for Elderly Patients with Metastatic Colorectal Cancer: A Phase II Trial

  2005cited by this paper
• A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer.

  2005cited by this paper
• Elderly patients with advanced colorectal cancer: which therapy is the safest?

  2005cited by this paper
• Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.

  2005cited by this paper
• Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale.

  2005cited by this paper
• Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials.

  2005cited by this paper
• FOLFOX alternated with FOLFIRI as first-line chemotherapy for metastatic colorectal cancer.

  2005cited by this paper
• Management of Colorectal Cancer in Elderly Patients

  2004cited by this paper
• FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.

  2004cited by this paper
• A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

  2004cited by this paper
• Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.

  2004cited by this paper
• Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer

  2004cited by this paper
• Participation of patients 65 years of age or older in cancer clinical trials.

  2003influential reference
• Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer.

  2003cited by this paper
• Survey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials

  2002cited by this paper
• Cancer screening in elderly patients: a framework for individualized decision making.

  2001cited by this paper
• A systematic overview of chemotherapy effects in colorectal cancer.

  2001cited by this paper
• Stage III colon cancers: why adjuvant chemotherapy is not offered to elderly patients.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Management of Cancer in the Older Person : A Practical Approach

  2000cited by this paper
• Management of cancer in the older person: a practical approach.

  2000cited by this paper
• Underrepresentation of patients 65 years of age or older in cancer-treatment trials.

  1999cited by this paper
• A multicenter, Phase II trial of weekly irinotecan (CPT‐11) in patients with previously treated colorectal carcinoma

  1999cited by this paper
• Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.

  1998cited by this paper
• Relationship Between Age at Diagnosis and Treatments

  1985cited by this paper
• Clinical trials

  1984cited by this paper
• Regression Models and Life-Tables

  year unknowncited by this paper

• Management of Elderly Colorectal Cancer Patients: A Comprehensive Review Encompassing Geriatric Assessment

  2025cites this paper
• Risks of hypertension and thromboembolism in patients receiving bevacizumab with chemotherapy for colorectal cancer: A systematic review and meta‐analysis

  2023cites this paper
• Controllable Regulation of Ag2S Quantum‐Dot‐Mediated Protein Nanoassemblies for Imaging‐Guided Synergistic PDT/PTT/Chemotherapy against Hypoxic Tumor

  2023cites this paper
• Update on the management of elderly patients with colorectal cancer

  2023cites this paper
• Benefit of intensive chemotherapy for elderly patients aged 80 years or older with metastatic colorectal cancer: a state-wide multicenter cohort study

  2021cites this paper
• Systematic Review of Treatments for Colorectal Metastases in Elderly Patients to Guide Surveillance Cessation Following Hepatic Resection for Colorectal Liver Metastases

  2021influential citation
• Clinical Effectiveness of Oncological Treatment in Metastatic Colorectal Cancer Is Independent of Comorbidities and Age

  2021cites this paper
• Outcomes following potentially curative therapies for older patients with metastatic colorectal cancer.

  2020cites this paper
• Systemic Therapy of Common Tumours in Older Patients: Challenges and Opportunities. A Young International Society of Geriatric Oncology Review Paper

  2020cites this paper
• First-line panitumumab plus capecitabine for the treatment of older patients with wild-type RAS metastatic colorectal cancer. The phase II, PANEL study.

  2020cites this paper
• Treatment guidelines of metastatic colorectal cancer in older patients from the French Society of Geriatric Oncology (SoFOG).

  2020cites this paper
• Current Treatment Strategies for Elderly Patients with Metastatic Colon Cancer

  2019cites this paper
• Efficacy of palliative chemotherapy in elderly patients with colorectal cancer

  2019cites this paper
• Current Trends in Systemic Therapies in Elderly Patients With Metastatic Colorectal Cancer

  2019cites this paper
• Age-dependent differences in first-line chemotherapy in patients with metastatic colorectal cancer: the DISCO study

  2018cites this paper
• What Chemotherapy Is Practicable in Aged Patients

  2018cites this paper
• Inclusion of elderly or frail patients in randomized controlled trials of targeted therapies for the treatment of metastatic colorectal cancer: A systematic review.

  2018cites this paper
• Hydrogen Sulfide-Activatable Second Near-Infrared Fluorescent Nanoassemblies for Targeted Photothermal Cancer Therapy.

  2018cites this paper
• Do we make progress in elderly patients with metastatic colorectal cancer?

  2018cites this paper
• Synchronous colorectal liver metastases: focus on the elderly

  2017cites this paper
• [Colorectal cancer in the elderly. Surgical treatment, chemotherapy, and contribution from geriatrics].

  2017cites this paper
• Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer.

  2017cites this paper
• Comparative Safety of Targeted Therapies for Metastatic Colorectal Cancer between Elderly and Younger Patients: a Study Using the International Pharmacovigilance Database

  2017cites this paper
• The effect of geriatric intervention in frail elderly patients receiving chemotherapy for colorectal cancer: a randomized trial (GERICO)

  2017cites this paper
• Evaluation post-commercialisation des médicaments en oncogériatrie : application au traitement du cancer colorectal métastatique

  2017cites this paper
• Bevacizumab plus chemotherapy in elderly patients with previously untreated metastatic colorectal cancer: single center experience

  2016cites this paper
• Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis

  2016cites this paper
• Sequential biological therapies in metastatic colorectal cancer (mCRC): a cost comparison analysis for wildtype RAS mCRC patients in Brazil

  2016cites this paper
• Thromboembolic Events Associated with Bevacizumab plus Chemotherapy for Patients with Colorectal Cancer: A Meta-Analysis of Randomized Controlled Trials.

  2016cites this paper
• Palliative chemotherapy in advanced colorectal cancer patients 80 years of age and older.

  2016cites this paper
• Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial).

  2015cites this paper
• Bevacizumab treatment in the elderly patient with metastatic colorectal cancer

  2015cites this paper
• Chemotherapy for colorectal cancer in the elderly.

  2015cites this paper
• Novel quality indicators for metastatic colorectal cancer management identify significant variations in these measures across treatment centers in Australia

  2015cites this paper
• First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours.

  2015cites this paper
• Chemotherapy in Elderly Patients with Colorectal Cancer

  2014cites this paper
• First-line mono-chemotherapy in frail elderly patients with metastatic colorectal cancer.

  2014cites this paper
• Role of cetuximab in first-line treatment of metastatic colorectal cancer.

  2014cites this paper
• Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. a meta-analysis

  2014cites this paper
• Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trials.

  2014cites this paper
• An update on the management of metastatic colorectal cancer in the elderly

  2014cites this paper
• de plus de 75 ans, en situation r eelle de soins

  2014cites this paper
• Treatment Strategy for Elderly Patients with Metastatic Colorectal Cancer: A Review of the Systemic Chemotherapy Options

  2013cites this paper
• Are we changing the way we treat older colorectal cancer patients? An update on therapeutic management strategies

  2013cites this paper
• Randomized Phase II Study of Capecitabine With or Without Oxaliplatin as First-line Treatment for Elderly or Fragile Patients With Metastatic Colorectal Cancer: A Prospective, Multicenter Trial of the Korean Cancer Study Group CO06-01

  2013cites this paper
• Targeted Therapies in Older Patients with Metastatic Colorectal Cancer

  2013cites this paper
• Non-steroidal anti-inflammatory treatment in cancer cachexia: A systematic literature review

  2013cites this paper
• Update on Antiangiogenic Therapy for Metastatic Colorectal Cancer TARGETING TUMOR ANGIOGENESIS

  2013cites this paper
• Bevacizumab in the Treatment of Elderly Patients with Metastatic Colorectal Cancer

  2013cites this paper
• VEGF Suppression: FDA Approved Antiangiogenic Agents for CRC

  2013cites this paper
• Retrospective Study as First-Line Chemotherapy Combined Anti-VEGF Antibody with Fluoropyrimidine for Frail Patients with Unresectable or Metastatic Colorectal Cancer

  2013cites this paper
• Safety of Bevacizumab in Treating Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis of All Randomized Clinical Trials

  2013cites this paper
• First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study.

  2012cites this paper
• 5-Fluorouracil or capecitabine in the treatment of advanced colorectal cancer: a pooled-analysis of randomized trials

  2012cites this paper
• Caplri (XelIri) Regimen for Advanced and Metastatic Colorectal or Esophogastric Cancer

  2012cites this paper
• The use of high dose d,l-leucovorin in first-line bevacizumab+mFOLFIRI treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab

  2012cites this paper
• Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer

  2012cites this paper
• Role of the Antiangiogenic Agent Bevacizumab in the Treatment of Elderly Patients with Metastatic Colorectal Cancer

  2011cites this paper
• Comorbidity, not age, is prognostic in patients with advanced pancreatic cancer receiving gemcitabine-based chemotherapy.

  2011cites this paper
• Metastatic colorectal cancer in the elderly: An overview of the systemic treatment modalities (Review).

  2011cites this paper
• Evaluation of efficacy and safety of FOLFIRI for elderly patients with gastric cancer: a first-line phase II study.

  2011cites this paper
• Feasibility and efficacy of capecitabine and FOLFIRI in patients aged 65 years and older with advanced colorectal cancer: a retrospective analysis

  2010cites this paper
• Treatment considerations in elderly colorectal cancer patients.

  2010cites this paper
• New developments in the adjuvant therapy of stage II colon cancer. Risk assessments in the older patient.

  2010cites this paper
• Bevacizumab plus Irinotecan-Based Regimens in the Treatment of Metastatic Colorectal Cancer

  2010cites this paper
• Pharmacoepidemiology and drug safety

  2009cites this paper